Based on the information you submitted
You have
Stage IIC
Melanoma
Introduction:
Patients with stage IIc disease has T4b disease (i.e., Breslow thickness greater than 4.0mm and with ulceration).
Survivor Outcome:
According to the 2018 AJCC data, for patients with stage IIC disease, the 5-year and 10-year melanoma-specific survival probability are 82% and 75%.
Treatment:
Adopted from NCCN Guideline 2022
For this group, the treatment involves excision of the tumor along with a standard surgical margin of 2 cm.
Sentinel lymph node biopsy (SLNB) is discussed and offered.
Routine imaging (e.g., X-ray or CT scan) or lab tests are not recommended.
In certain cases, your physicians, specifically the medical oncologists may discuss the role of adjuvant treatment.
INTERVIEW WITH THE EXPERTS
01
Dr. Thomas Wang explains the sentinel lymph node biopsy (SLNB) procedure
02
Dr. Thomas Wang describes explains the sentinel lymph node biopsy procedure
03
Dr. Thomas Wang discusses which patients need the sentinel lymph node biopsy (SLNB)
04
Dr. Dan Coit explains sentinel lymph node biopsy (SLNB), the consultation process for the sentinel lymph node biopsy (SLNB), and the day of the surgery
05
Dr. Dan Coit discusses the complications associated with the sentinel lymph node biopsy
06
Dr. Dan Coit discusses the controversy associated with the sentinel lymph node biopsy procedure
07
Dr. Richard Carvajal discusses the role of adjuvant treatment for stage IIb/IIc disease
08
Dr. April Salama discusses the role of adjuvant treatment for stage IIb/IIc disease
09
Dr. Paul Chapman discusses the role of adjuvant treatment for stage IIb/IIc disease starting at minute 7:50. Before that Dr. Chapman discusses the role of adjuvant treatment for stage III disease.